Mounjaro® and constipation

Constipation across Mounjaro® data sets

The US label’s Table 1 pools SURPASS-1 and SURPASS-5, in which 718 adults with type 2 diabetes took tirzepatide for an average of 36.6 weeks ^[1]. Canada prints the same pool unrounded and adds seven phase 3 trials with 5,119 people on tirzepatide ^[4]. SURPASS-CVOT, a separate trial of 6,647 adults on Mounjaro® with diabetes and heart disease, compared it with dulaglutide rather than placebo over a median of 210.1 weeks ^[1].

A low baseline, a flat dose line, a higher long-term figure

Only about 1% of people on placebo reported constipation, one of the lowest placebo figures in the table, and the rate barely moves between 5 mg and 15 mg in either the US or the larger Canadian pool ^[1][4]. That pattern differs from nausea, which climbs with dose. Constipation is also missing from the label’s sentence about timing, which says most nausea, vomiting and diarrhea came during dose escalation and then eased; the label gives no information on when constipation starts or how long it lasts ^[1].

The SURPASS-CVOT figure of 13% is about double the placebo-controlled pool ^[1]. That trial enrolled older adults, average age 64, with diabetes for about 15 years and established heart or blood vessel disease, and followed them for roughly four years, so the two numbers describe different people and time spans ^[1]. The European information points the same way from another angle: constipation is “very common”, at least 1 in 10, in its weight-management, heart, sleep apnoea and heart failure trials, but “common” in adult and pediatric diabetes trials ^[3].

What reviews and real-world data add

A meta-analysis of tirzepatide trials in type 2 diabetes found constipation significantly more frequent than with placebo at all three doses, and a trial sequential analysis judged that difference conclusive. Overall, the authors described tirzepatide’s stomach side effects as higher than placebo and insulin but comparable with GLP-1 receptor agonists ^[5].

Outside trials, a US new-user cohort study matched tens of thousands of adults with type 2 diabetes starting tirzepatide, semaglutide or dulaglutide. A combined outcome of severe stomach and bowel events, including severe constipation, bowel obstruction, gastroparesis, pancreatitis and gallbladder disease, occurred at similar rates across the three medicines ^[6]. As an observational study it cannot fully rule out differences between the groups, but it suggests tirzepatide does not stand apart from its class on serious bowel events.

Why tirzepatide may slow the bowel

What the label supports: tirzepatide delays stomach emptying, most strongly after the first dose, and lowers food intake ^[1]. The label does not link either effect directly to constipation.

What researchers describe: a review of GLP-1 medicines and tirzepatide notes that, besides slowing the stomach, they slow movement through the small intestine, and that these motility effects can occasionally cause problems such as bowel obstruction ^[7]. It is plausible that eating much less, with less fibre and sometimes less fluid, adds to this; the NIH lists low fibre, too little fluid and slow movement of stool through the colon among causes of constipation ^[8]. None of this has been measured specifically for constipation on tirzepatide.

Severe constipation, impaction and blockage

Section 6.2 of the US label lists reports received after approval, without frequencies: severe constipation including fecal impaction, a hard mass of stool stuck in the rectum, as well as ileus and intestinal obstruction ^[1]. Canada lists ileus among its post-market reactions too ^[4]. The labels stress that voluntary reports cannot show how often an event happens or prove the medicine caused it.

Section 5.6 adds that Mounjaro® can cause stomach and bowel reactions that are sometimes severe and is not recommended in severe gastroparesis ^[1]. Canada asks prescribers to monitor anyone who develops severe stomach symptoms and to consider changing the dose or stopping ^[4]. Constipation with constant belly pain, vomiting or an inability to pass gas is the combination the NIH says needs a doctor right away ^[8].

Other causes worth ruling out

The NIH lists many medicines and supplements that can make constipation worse, including iron supplements, antacids containing aluminium or calcium, opioid pain medicines, some antidepressants, calcium channel blockers and diuretics ^[8]. If one of these began in the same weeks as Mounjaro®, both deserve a look.

Life changes count too: pregnancy, ageing, travel, a new eating pattern and putting off the urge to go can all slow the bowel, as can conditions such as diabetes itself, an underactive thyroid and irritable bowel syndrome ^[8]. Weight loss without trying, blood in the stool or a family history of bowel cancer are reasons to see a doctor rather than assume the medicine is to blame ^[8].

What may help

The Mounjaro® documents do not give self-care advice for constipation. The NIH and MedlinePlus do; check any change with your prescriber, especially if you have kidney disease or limits on fluids.

• Add fibre-rich foods such as whole grains, beans and lentils, fruit with the skin on and vegetables a little at a time, because a sudden jump can cause gas and bloating ^[10][11].
• Drink plenty of water and other liquids, especially when you add fibre or a fibre supplement ^[9][11].
• Keep up regular physical activity and do not skip meals ^[9][10].
• Go when you feel the urge, and give yourself time; some people find a regular slot after breakfast helps ^[9][10].
• Your provider may suggest a laxative for a short time. MedlinePlus advises against taking one if you have severe stomach pain, nausea or vomiting, and against using it for more than a week without advice ^[9][10].
• Because tirzepatide slows stomach emptying and can change how tablets are absorbed, ask your pharmacist before adding a laxative or supplement ^[1].

Before your appointment

Write down the date of your last bowel movement, how stools have changed, whether you are passing gas, and whether pain, bloating, nausea or vomiting came with it. Note your last injection and dose change and any new medicines or supplements. That gives your prescriber what they need to judge whether this is ordinary constipation or something to examine, and whether anything about your treatment should change.

Mounjaro® is a registered trademark of Eli Lilly and Company. PepLabo is not affiliated with or endorsed by Eli Lilly and Company.

When to get help